Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
P/B ratio for Mirum Pharmaceuticals, Inc. (MIRM)
P/B ratio as of 2023: 4.85
According to Mirum Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.85. At the end of 2022 the company had a P/B ratio of -1.68.
P/B ratio history for Mirum Pharmaceuticals, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 4.85 |
| 2022 | -1.68 |
| 2021 | 4.02 |
| 2020 | -2.55 |
| 2019 | -8.06 |
| 2018 | -29.42 |